Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elaine Y. L. Blair"'
Autor:
Michael Stormon, Kay Montgomery, Elisabeth M Hodson, Katherine R. Stephen, Peter J. Shaw, Andrew J. McLachlan, John C. Coakley, John W. Earl, Elaine Y. L. Blair, Christa E. Nath, L. Zeng
Publikováno v:
British Journal of Clinical Pharmacology. 70:567-579
AIMS To characterize the population pharmacokinetics of mycophenolic acid (MPA) and evaluate dose regimens using a simulation approach and accepted therapeutic drug monitoring targets in children and young people undergoing blood or marrow, kidney an
Autor:
Peter J. Shaw, John C. Coakley, Elaine Y. L. Blair, K. Stephen, L. Zeng, Christa E. Nath, Andrew J. McLachlan, John W. Earl
Publikováno v:
Antimicrobial Agents and Chemotherapy. 53:2918-2927
Acyclovir is effective in the prevention and treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. The aim of this study was to characterize the population pharmacokinetics of acyclovir observed following treatment with
Publikováno v:
The Journal of Clinical Pharmacology. 46:1370-1378
Systematic evidence regarding herb-drug interactions is lacking. This study investigated herb-drug interactions with warfarin. S-warfarin concentration and response (prothrombin complex activity) data from healthy subjects (n = 24) who received a sin
Autor:
David Farlow, Graham J. Mann, Michael T. Collins, Mark Wong, Stephen P. Ackland, Janelle M. Hoskins, Scott R. Evans, Christine L. Clarke, Andrew J. McLachlan, Laurent P. Rivory, Rosemary L. Balleine, Elaine Y. L. Blair, Howard Gurney, Madhu B. Garg
Publikováno v:
Journal of Clinical Oncology. 24:2448-2455
Purpose Marked interindividual variation in drug disposition and toxicity pose an ongoing challenge to chemotherapy dosage individualization. The aim of this study was to evaluate pretreatment clinical features, genotype and functional indicators of
Publikováno v:
British Journal of Clinical Pharmacology. 57:416-426
Aims To investigate the population pharmacokinetics of raltitrexed in patients with advanced solid tumours and to identify patient covariates contributing to the interpatient variability in the pharmacokinetics of raltitrexed. Methods Patient covaria
Autor:
Laurent P. Rivory, Elaine Y. L. Blair, Andrew J. McLachlan, Stephen Clarke, Kellie A. Slaviero
Publikováno v:
British Journal of Clinical Pharmacology. 57:44-53
Aims Previous pharmacokinetic studies of the 3-weekly regimen (100 mg m−2 every 3 weeks) of docetaxel have shown that docetaxel clearance is affected by liver function, body surface area, age, serum α1-acid glycoprotein and cytochrome P450 3A4 (CY
Autor:
Lihua, Zeng, Elaine Y L, Blair, Christa E, Nath, Peter J, Shaw, John W, Earl, Katherine, Stephen, Kay, Montgomery, John C, Coakley, Elisabeth, Hodson, Michael, Stormon, Andrew J, McLachlan
Publikováno v:
British journal of clinical pharmacology. 70(4)
To characterize the population pharmacokinetics of mycophenolic acid (MPA) and evaluate dose regimens using a simulation approach and accepted therapeutic drug monitoring targets in children and young people undergoing blood or marrow, kidney and liv
Autor:
Kellie A, Slaviero, Stephen J, Clarke, Andrew J, McLachlan, Elaine Y L, Blair, Laurent P, Rivory
Publikováno v:
British journal of clinical pharmacology. 57(1)
Previous pharmacokinetic studies of the 3-weekly regimen (100 mg m(-2) every 3 weeks) of docetaxel have shown that docetaxel clearance is affected by liver function, body surface area, age, serum alpha1-acid glycoprotein and cytochrome P450 3A4 (CYP3